Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04547998 · ClinicalTrials.gov registry record · NA
Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
A NA study, sponsored by Avita Medical.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT04547998 is a NA study that has completed, run by Avita Medical. The registered enrollment target is 25 participants.
The verdict
NCT04547998, a NA study, has completed, sponsored by Avita Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a prospective blinded within-subject randomized study to evaluate the application of Spray-On Skin™ Cells, prepared using the RECELL® Device for safe and effective repigmentation of ablated stable vitiligo lesions.
Interventions
- DEVICE Control Intervention (UVB)
- DEVICE Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-09-10 |
| Est. Completion | 2023-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04547998
The ClinicalTrials.gov registry entry for NCT04547998 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avita Medical, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control Intervention (UVB) is the first listed.
NCT04547998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04547998 about?
NCT04547998 is a clinical study titled "Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions". This is a prospective blinded within-subject randomized study to evaluate the application of Spray-On Skin™ Cells, prepared using the RECELL® Device for safe and effective repigmentation of ablated stable vitiligo lesions.
What is the current status of trial NCT04547998?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2020-09-10. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT04547998?
The interventions under investigation include: Control Intervention (UVB) (DEVICE), Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB) (DEVICE).
Who is sponsoring clinical trial NCT04547998?
This trial is sponsored by Avita Medical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.